

Table 6. Large scale randomized trials evaluating ultrahypofractionated EBRT in localized prostate cancer

Trial	Planned accrual	Population	Primary Endpoint	Ultrahypofractionated Regimen	Comparator Regimen	Current Status
HEAT NCT01794403	456	LR and IR	Biochemical or clinical failure	3625 cGy in 5 fractions	7020 cGy in 26 fractions	Accruing
HYPO-RT-PC ISRCTN45905321	1200	IR	Biochemical or clinical failure	4270 cGy in 7 fractions	7800 cGy in 39 fractions	Accrual complete
NRG-GU005	606	IR	HRQOL Toxicity assessment	3625 cGy in 5 fractions	7000 cGy in 28 fractions	Accruing
PACE B NCT01584258	858	LR and IR (Gleason score ≤ 3+4)	Biochemical or clinical failure	3625 cGy in 5 fractions	7800 cGy in 39 fractions or 6200 cGy in 20 fractions	Accrual complete

LR = low-risk; IR = intermediate-risk